See more : The Green Organic Dutchman Holdings Ltd. (TGODF) Income Statement Analysis – Financial Results
Complete financial analysis of Taiwan Liposome Company, Ltd. (TLC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taiwan Liposome Company, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 1stdibs.Com, Inc. (DIBS) Income Statement Analysis – Financial Results
- Kakuyasu Group Co., Ltd. (7686.T) Income Statement Analysis – Financial Results
- Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) Income Statement Analysis – Financial Results
- NGK Spark Plug Co., Ltd. (5334.T) Income Statement Analysis – Financial Results
- Canon Marketing Japan Inc. (8060.T) Income Statement Analysis – Financial Results
Taiwan Liposome Company, Ltd. (TLC)
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 101.93M | 209.14M | 62.32M | 49.64M | 41.67M | 59.77M | 95.92M | 158.64M | 240.66M | 78.23M | 36.65M | 25.97M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 101.93M | 209.14M | 62.32M | 49.64M | 41.67M | 59.77M | 95.92M | 158.64M | 240.66M | 78.23M | 36.65M | 25.97M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 967.50M | 860.42M | 832.58M | 813.25M | 736.88M | 634.85M | 664.45M | 470.24M | 374.58M | 257.33M | 209.57M | 166.40M |
| General & Administrative | 145.77M | 166.38M | 147.74M | 134.87M | 141.49M | 138.32M | 102.99M | 98.14M | 55.85M | 46.03M | 45.28M | 46.68M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 145.77M | 166.38M | 147.74M | 134.87M | 141.49M | 138.32M | 102.99M | 98.14M | 55.85M | 46.03M | 45.28M | 46.68M |
| Other Expenses | -28.23M | -16.05M | -26.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.09B | 1.01B | 954.09M | 948.12M | 878.37M | 773.17M | 767.43M | 568.38M | 430.44M | 303.36M | 254.85M | 213.09M |
| Cost & Expenses | 1.09B | 1.01B | 954.09M | 948.12M | 878.37M | 773.17M | 767.43M | 568.38M | 430.44M | 303.36M | 254.85M | 213.09M |
| Interest Income | 1.19M | 7.40M | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 472.00K | 311.00K | 298.00K | 258.00K |
| Interest Expense | 16.35M | 23.66M | 9.89M | 3.39M | 2.94M | 2.59M | 1.31M | 1.63M | 2.14M | 2.39M | 2.31M | 1.21M |
| Depreciation & Amortization | 56.17M | 71.40M | 47.46M | 52.50M | 75.24M | 60.93M | 51.51M | 30.18M | 25.73M | 23.12M | 19.07M | 20.91M |
| EBITDA | -909.66M | -708.34M | -843.36M | -817.13M | -745.57M | -611.72M | -579.75M | -368.80M | -159.01M | -191.08M | -168.69M | -161.82M |
| EBITDA Ratio | -892.45% | -338.69% | -1,353.19% | -1,646.28% | -1,789.06% | -1,023.43% | -604.40% | -232.47% | -66.07% | -244.25% | -460.26% | -623.22% |
| Operating Income | -983.11M | -801.61M | -891.77M | -898.49M | -836.70M | -713.40M | -671.51M | -409.74M | -189.78M | -225.13M | -218.20M | -187.12M |
| Operating Income Ratio | -964.51% | -383.29% | -1,430.85% | -1,810.19% | -2,007.72% | -1,193.55% | -700.06% | -258.27% | -78.86% | -287.77% | -595.36% | -720.67% |
| Total Other Income/Expenses | 933.00K | -1.80M | -8.94M | 25.48M | 12.95M | 38.16M | 38.94M | 9.12M | 2.90M | 8.54M | 28.13M | 3.18M |
| Income Before Tax | -982.18M | -803.40M | -900.71M | -873.01M | -823.75M | -675.24M | -632.57M | -400.61M | -186.88M | -216.59M | -190.07M | -183.94M |
| Income Before Tax Ratio | -963.60% | -384.15% | -1,445.20% | -1,758.86% | -1,976.66% | -1,129.70% | -659.46% | -252.52% | -77.65% | -276.86% | -518.61% | -708.41% |
| Income Tax Expense | 1.13M | 4.12M | 867.00K | 951.00K | 563.00K | 450.00K | 292.00K | 359.00K | 251.00K | 394.00K | 142.00K | 127.00K |
| Net Income | -983.31M | -807.52M | -901.57M | -873.96M | -824.32M | -675.69M | -632.86M | -400.97M | -187.13M | -216.99M | -190.21M | -184.07M |
| Net Income Ratio | -964.71% | -386.12% | -1,446.59% | -1,760.78% | -1,978.01% | -1,130.46% | -659.77% | -252.75% | -77.76% | -277.36% | -519.00% | -708.90% |
| EPS | -24.89 | -24.64 | -28.75 | -31.50 | -29.78 | -24.50 | -23.08 | -16.44 | -9.50 | -14.60 | -18.18 | -17.92 |
| EPS Diluted | -24.89 | -24.64 | -28.75 | -31.50 | -29.78 | -24.50 | -23.08 | -16.44 | -9.50 | -14.60 | -18.18 | -17.92 |
| Weighted Avg Shares Out | 39.51M | 32.77M | 31.36M | 27.74M | 27.68M | 27.58M | 27.42M | 24.39M | 19.70M | 14.86M | 10.46M | 10.27M |
| Weighted Avg Shares Out (Dil) | 39.51M | 32.77M | 31.36M | 27.74M | 27.68M | 27.58M | 27.42M | 24.39M | 19.70M | 14.86M | 10.46M | 10.27M |
TLC Announces Details of Stock Swap Transactions
TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company's board-approved stock...
TLC Stock Price: 28.69% Increase Explanation
The stock price of TLC (Nasdaq: TLC) increased by 28.69% yesterday. This is why it happened.
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus...
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average.
TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment
India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage. AmphoTLC is a liposomal amphotericin B...
TLC Stock Price: Over 6% Increase Pre-Market Explanation
The stock price of Taiwan Liposome Company (NASDAQ: TLC) increased by over 6% pre-market. This is why it happened.
TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard...
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.
TLC Stock Price: Over 15% Increase Explanation
The stock price of Taiwan Liposome Company (NASDAQ: TLC) increased by over 15% during intraday trading this morning. This is why it happened.
InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential...
Source: https://incomestatements.info
Category: Stock Reports